loading page

Potential cancer risk with omalizumab: a disproportionality analysis of the WHO’s VigiBase pharmacovigilance database
  • +1
  • Diogo Mota,
  • Tiago Rama,
  • Milton Severo,
  • André Moreira
Diogo Mota
Faculty of Medicine
Author Profile
Tiago Rama
Faculdade de Medicina da Universidade do Porto, Porto, Portugal & Centro Hospitalar São João
Author Profile
Milton Severo
Faculty of Medicine, University of Porto
Author Profile
André Moreira
Faculty of Medicine
Author Profile

Peer review status:UNDER REVIEW

10 Apr 2021Submitted to Allergy
12 Apr 2021Submission Checks Completed
12 Apr 2021Assigned to Editor
13 Apr 2021Reviewer(s) Assigned
25 Apr 2021Review(s) Completed, Editorial Evaluation Pending
29 May 20211st Revision Received
31 May 2021Submission Checks Completed
31 May 2021Assigned to Editor
01 Jun 2021Reviewer(s) Assigned
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending